Clinical Trials Logo

Alzheimer's Disease clinical trials

View clinical trials related to Alzheimer's Disease.

Filter by:

NCT ID: NCT01251718 Completed - Alzheimer's Disease Clinical Trials

Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease

Start date: December 1, 2010
Phase:
Study type: Observational

To investigate the clinical safety and effectiveness of donepezil hydrochloride administration in patients with mild or moderate Alzheimer's Disease

NCT ID: NCT01249196 Completed - Alzheimer's Disease Clinical Trials

A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease

Start date: May 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of SK-PC-B70M in patients with mild to moderate Alzheimer's disease.

NCT ID: NCT01238991 Terminated - Alzheimer's Disease Clinical Trials

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Start date: December 2010
Phase: Phase 2
Study type: Interventional

The purpose of this long term extension study is to assess safety, tolerability and immunogenicity of ACC-001 with QS-21 adjuvant in Japanese subjects with mild to moderate AD who were randomized in the preceding P2 double blind studies.

NCT ID: NCT01238458 Enrolling by invitation - Alzheimer's Disease Clinical Trials

Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers

[18F]AV-45
Start date: November 2009
Phase: Phase 2
Study type: Interventional

This study will recruit a total of 150 evaluable subjects (30 cognitively normal volunteers, and 60 MCI(Mild cognitive impairment), and 60 AD(Alzheimer's disease), respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events. This study is expected to be completed in a period of 3 years.

NCT ID: NCT01230853 Completed - Alzheimer's Disease Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Start date: August 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study will be to evaluate the safety and tolerability of lecanemab at sequentially ascending doses in subjects with mild to moderate Alzheimer's disease (AD).

NCT ID: NCT01227564 Completed - Alzheimer's Disease Clinical Trials

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This study in individuals with early Alzheimer's disease is designed to assess:(1) safety and tolerability (2) the capacity of ACC-001 and QS-21 adjuvant to reduce brain amyloid load as measured by positron emission tomography (PET) scans.

NCT ID: NCT01227252 Completed - Alzheimer's Disease Clinical Trials

A Safety Study of LY2886721 Multiple Doses in Healthy Subjects

Start date: December 2010
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 multiple doses, how the body handles the drug, and the drug's effect on the body.

NCT ID: NCT01225809 Completed - Alzheimer´s Disease Clinical Trials

AD01 Follow up Extension Visit

Start date: September 2010
Phase: N/A
Study type: Observational

Patients who were vaccinated with AFFITOPE AD01 during AFFiRiS001 will undergo a long-term follow-up period to get more information regarding the safety profile of AFFITOPE AD01.

NCT ID: NCT01224106 Completed - Alzheimer's Disease Clinical Trials

A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease

Scarlet Road
Start date: November 30, 2010
Phase: Phase 3
Study type: Interventional

This multi-center, randomized, double-blind, placebo-controlled parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in participants with prodromal Alzheimer's Disease. Participants will be randomized to receive subcutaneous (SC) injections of either gantenerumab or placebo. Participants who consent to be part of the sub study will undergo positron emission tomography (PET) scanning to assess brain amyloid. The anticipated time on study treatment is 104 weeks in Part 1, with an option for an additional up to 2 years of treatment in Part 2, followed by an open-label extension (Part 3) until July 2020. The dosing for Parts 1 and 2 was stopped after a planned futility interim analysis showed a low probability of meeting the primary outcome measure with the doses studied. The study has converted to open-label to investigate higher gantenerumab doses.

NCT ID: NCT01221259 Completed - Alzheimer's Disease Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects

Start date: January 2010
Phase: Phase 1
Study type: Interventional

This study is designed as a single ascending dose study in healthy subjects to evaluate safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) in plasma and Cerebrospinal (CSF) following single oral doses of E2212.